325 related articles for article (PubMed ID: 20043763)
1. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
Chen NF; Smith ZA; Stiner E; Armin S; Sheikh H; Khoo LT
J Neurosurg Spine; 2010 Jan; 12(1):40-6. PubMed ID: 20043763
[TBL] [Abstract][Full Text] [Related]
2. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
Singh K; Nandyala SV; Marquez-Lara A; Cha TD; Khan SN; Fineberg SJ; Pelton MA
Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
[TBL] [Abstract][Full Text] [Related]
3. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1137-45. PubMed ID: 23354111
[TBL] [Abstract][Full Text] [Related]
4. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
[TBL] [Abstract][Full Text] [Related]
5. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2).
Wong DA; Kumar A; Jatana S; Ghiselli G; Wong K
Spine J; 2008; 8(6):1011-8. PubMed ID: 18037352
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic ectopic intracanal ossification after transforaminal lumbar interbody fusion with rhBMP-2.
Lehman RA; Kang DG
Spine J; 2012 Jun; 12(6):530-1. PubMed ID: 22682741
[No Abstract] [Full Text] [Related]
7. Retrograde ejaculation following single-level anterior lumbar surgery with or without recombinant human bone morphogenetic protein-2 in 5 randomized controlled trials: clinical article.
Burkus JK; Dryer RF; Peloza JH
J Neurosurg Spine; 2013 Feb; 18(2):112-21. PubMed ID: 23199378
[TBL] [Abstract][Full Text] [Related]
8. Vertebral osteolysis originating from subchondral cyst end plate defects in transforaminal lumbar interbody fusion using rhBMP-2. Report of two cases.
Balseiro S; Nottmeier EW
Spine J; 2010 Jul; 10(7):e6-e10. PubMed ID: 20488766
[TBL] [Abstract][Full Text] [Related]
9. Revision surgery after interbody fusion with rhBMP-2: a cautionary tale for spine surgeons.
Rodgers SD; Marascalchi BJ; Grobelny BT; Smith ML; Samadani U
J Neurosurg Spine; 2013 Jun; 18(6):582-7. PubMed ID: 23560709
[TBL] [Abstract][Full Text] [Related]
10. Clinical and radiographic outcomes using local bone shavings as autograft in minimally invasive transforaminal lumbar interbody fusion.
Kasliwal MK; Deutsch H
World Neurosurg; 2012 Jul; 78(1-2):185-90. PubMed ID: 22120378
[TBL] [Abstract][Full Text] [Related]
11. Neuroforaminal chondrocyte metaplasia and clustering associated with recombinant bone morphogenetic protein-2 usage in transforaminal lumbar interbody fusion.
Christensen TJ; Annis P; Hohl JB; Patel AA
Spine J; 2014 Jun; 14(6):e23-8. PubMed ID: 24291359
[TBL] [Abstract][Full Text] [Related]
12. Ectopic bone.
Traynelis VC
J Neurosurg Spine; 2010 Jan; 12(1):39. PubMed ID: 20043762
[No Abstract] [Full Text] [Related]
13. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2.
Villavicencio AT; Burneikiene S; Nelson EL; Bulsara KR; Favors M; Thramann J
J Neurosurg Spine; 2005 Dec; 3(6):436-43. PubMed ID: 16381205
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic morphogenetic protein vs. recombinant human bone morphogenetic protein-2 in lumbar interbody fusion procedures: a radiographic and economic analysis.
Roh JS; Yeung CA; Field JS; McClellan RT
J Orthop Surg Res; 2013 Dec; 8():49. PubMed ID: 24373225
[TBL] [Abstract][Full Text] [Related]
15. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Hoffmann MF; Jones CB; Sietsema DL
Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
[TBL] [Abstract][Full Text] [Related]
16. Complications associated with recombinant human bone morphogenetic protein use in pediatric craniocervical arthrodesis.
Lindley TE; Dahdaleh NS; Menezes AH; Abode-Iyamah KO
J Neurosurg Pediatr; 2011 May; 7(5):468-74. PubMed ID: 21529186
[TBL] [Abstract][Full Text] [Related]
17. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
[TBL] [Abstract][Full Text] [Related]
18. Minimally invasive transforaminal lumbar interbody fusion: one surgeon's learning curve.
Nandyala SV; Fineberg SJ; Pelton M; Singh K
Spine J; 2014 Aug; 14(8):1460-5. PubMed ID: 24290313
[TBL] [Abstract][Full Text] [Related]
19. Osteolysis in transforaminal lumbar interbody fusion with bone morphogenetic protein-2.
Knox JB; Dai JM; Orchowski J
Spine (Phila Pa 1976); 2011 Apr; 36(8):672-6. PubMed ID: 21217443
[TBL] [Abstract][Full Text] [Related]
20. Heterotopic ossification associated with recombinant human bone morphogenetic protein-2 (infuse) in posterolateral lumbar spine fusion: a case report.
Anderson CL; Whitaker MC
Spine (Phila Pa 1976); 2012 Apr; 37(8):E502-6. PubMed ID: 22020605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
